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POSEIDON groups 1 and 2 patients respond poorly (<4 oocytes retrieved) or
sub-optimally (4–9 oocytes retrieved) to gonadotropin stimulation despite the presence
of adequate ovarian parameters, which negatively affect their cumulative chances of
delivering a baby using Assisted Reproductive Technology. A polygenic trait involving
gonadotropins and/or their receptors seems to be the primary pathophysiology
mechanism explaining this phenomenon. The clinical management is mainly focused
on maximizing oocyte yield as to increase the likelihood of having at least one euploid
embryo for transfer. Indices such as FORT (follicle output rate) and FOI (follicle-to-oocyte
index) may be used to determine if the ovarian reserve was properly explored during
a previous ovarian stimulation. Testing for the presence of common polymorphisms
affecting gonadotropins and/or their receptors can also be considered to identify patients
at risk of hypo-response. An individualized estimation of the minimum number of
oocytes needed to obtain at least one euploid embryo can assist counseling and
treatment planning. Among currently existing pharmacological interventions, use of
recombinant FSH in preference over urinary gonadotropin preparations, FSH dosage
increase, and use of rLH supplementation may be considered -alone or combined- for
optimally managing POSEIDON’s groups 1 and 2 patients. However, given the recent
introduction of the POSEIDON criteria, there is still a lack of studies examining the role of
interventions specifically to patients classified as groups 1 and 2, thus making it an area
for open research.
Keywords: hypo-response, ovarian stimulation, Assisted Reproductive Technology, ovarian reserve, follicle-
to-oocyte index, POSEIDON criteria, suboptimal response, ART calculator
INTRODUCTION
The primary goal of Assisted Reproductive Technology (ART) is to provide effective and safe
personalized solutions to help infertile couples obtain a live birth. This objective should be attained
with the mindset of securing the shortest time to live birth while avoiding negative consequences
for the mother and newborns. In this regard, the transfer of a single embryo at the blastocyst
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stage provides a higher implantation rate than the transfer of
a cleavage stage embryo and limits the occurrence of multiple
pregnancies (1–4). ART failure is indeed a leading cause of
treatment dropout and is associated with an impairment of the
psychological wellness of treated couples (5–7). Furthermore, the
higher the number of ovarian stimulation (OS) cycles the higher
the financial burden on couples, with potential long-term effects
on general well-being (8). Thus, ART programs should strive to
obtain a single live-birth using the least number of OS cycles
as possible.
The novel Patient-Oriented Strategies Encompassing
IndividualizeD Oocyte Number (POSEIDON) criteria (9–11)
were introduced to help clinicians explore the possibility of
using patient-oriented strategies to obtain the number of oocytes
needed to achieve at least one euploid embryo for transfer
in low prognosis women undergoing ART, as these patients
represent the most vulnerable group concerning treatment
failure and treatment dropout. A clear definition of the low
prognosis patient population is, therefore, essential to avoid
heterogeneity and allow the use of personalized management
to achieve the intended goal. In brief, POSEIDON patients are
subdivided into four subgroups based on a combination of
factors including (i) age, (ii) results of functional and biological
ovarian reserve markers, such as Antral Follicle Count (AFC)
and Anti-Müllerian Hormone (AMH), and (iii) ovarian response
concerning the number of oocytes retrieved in previous OS if
this information was available (Figure 1). In practical terms, the
POSEIDON criteria stratify the low prognosis patients in two
main categories based on oocyte yield, namely, the “expected”
low ovarian response (Group 3 and 4) and the “unexpected” low
ovarian response (Groups 1 and 2).
POSEIDON’s groups 1 and 2 encompass women who had
poor (<4) or suboptimal (4–9) number of oocytes retrieved after
a conventional OS despite the presence of an adequate ovarian
reserve, defined by an AFC of ≥5 and/or an AMH ≥1.2 ng/mL.
Indeed, retrieval of fewer than 10 oocytes is associated with
decreased cumulative live birth rates (CLBR) (12). Among
women with normal ovarian reserve, 10–15 oocytes seem to be
the optimal target for increasing the likelihood of live birth rate
in fresh embryo transfer (ET) cycles (13). However, retrieval of
more than 15 oocytes might be advantageous concerning CLBR,
i.e., when all fresh and frozen-thawed ETs are considered (12, 14).
Thus, given a patient who fits POSEIDON’s groups 1 or 2, the
final goal would be to find ways to maximize oocyte yield aiming
at obtaining more than 9 oocytes at the end of stimulation.
In this paper, we review the pathophysiology and discuss the
available treatment strategies of low prognosis women according
to POSEIDON’s groups 1 and 2.
UNEXPECTED SUBOPTIMAL OR LOW
OOCYTE NUMBER AND ITS ASSOCIATION
WITH OVARIAN HYPO-RESPONSE TO
GONADOTROPIN STIMULATION
Patients who fit POSEIDON’s groups 1 and 2 criteria should
be critically assessed by looking at two indices, namely, the
FORT (follicle output rate) and the FOI (follicle-to-oocyte
index). The follicle output rate (FORT) measures the consistency
between the pool of antral follicles at the beginning of OS
and the number of pre-ovulatory follicles at the end of
stimulation (15, 16). Along the same lines, the FOI assesses
the consistency between the pool of antral follicles at the
beginning of OS and the number of oocytes retrieved at oocyte
pick-up (Figure 2). Thus, a discrepancy between the available
antral follicle pool and the number of pre-ovulatory follicles
at the end of stimulation (e.g., FORT<50%), or the number
of retrieved oocytes (e.g., FOI <50%) is suggestive of hypo-
response to gonadotropin stimulation, albeit other contributory
causes might exist as depicted in Figure 3 (17). The advantages
and shortcomings of using FOI and FORT to identify hypo-
responders to gonadotropin stimulation have been discussed in
detail elsewhere (17).
The pathophysiology mechanisms explaining the hypo-
response to gonadotropin stimulation, also known as “ovarian
resistance” to gonadotropin stimulation, are not fully understood.
However, environmental contaminants, as well as specific
genotypic traits have been hypothesized as possible contributory
factors (17–21) (Figure 3). In particular, genetic polymorphisms
affecting the gonadotropins and their receptors might impact OS
outcomes (22, 23). Such polymorphisms include those affecting
the FSH receptor genes, such as FSHR c.2039 A>G (rs6166)
(24, 25), FSH β chain [FSHB−211 G>T (rs10835638)] (26), and
FSH promoter region [FSHR−29 G>A (rs1394205)] (27, 28). Of
particular interest is the FSHR polymorphism (rs6166), which has
been implicated in ovarian resistance to exogenous gonadotropin
(24). The single nucleotide polymorphism SNP (rs6166), known
as Serine680 (Ser680) variant, causes the replacement of Asn with
Ser at the 680 position and is located in the intracellular domain
of the FSH receptor protein (29, 30).
Interestingly, it has been reported that Ser680 carriers with
polycystic ovarian syndrome show resistance to clomiphene
citrate (31). Another variant in a promoter region of FSHR,
namely FSHR, 29 G>A), was associated with negative effects
during OS. In a study by Achrekar et al. involving patients
undergoing OS for ART, women homozygous for the rs1394205
variant genotype AA had a lower number of oocytes and
lower pregnancy rates than those with the GG genotype (32).
This observation was confirmed in a more extensive study
by Desai et al. (27). These authors retrospectively evaluated
100 normogonadotropic women with regular menses who were
candidates for IVF. The carriers of AA genotype showed a
lower number of oocytes retrieved and a higher consumption
of exogenous gonadotropin than GG carriers. As for the FSH
β chain polymorphism (rs10835638), a study involving 169
healthy women, and 186 infertile women suggested that this
polymorphism is associated with significantly higher FSH and LH
levels in both healthy and female infertility patients (33). In this
report, the T-allele carriers were found more frequently among
idiopathic infertility cases, a fact that could be explained by the
influence of this particular polymorphism on FSHR function
(26, 34, 35).
A systematic review and meta-analysis published in 2018
summarized the data of 33 studies regarding the clinical relevance
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FIGURE 1 | Poseidon criteria of low prognosis patients in ART. Four distinct groups of low prognosis patients can be established based on quantitative and qualitative
parameters, namely: 1. The age of the patient and the expected embryo aneuploidy rate; 2. Ovarian biomarkers (antral follicle count [AFC] and/or anti-Müllerian
hormone [AMH]), and 3. The ovarian response of the patient in terms of oocyte quantity provided a previous cycle of stimulation was carried out. Art drawing by Chloé
Xilinas, EXCEMED, Rome, Italy. Adapted from Esteves et al. (10).
FIGURE 2 | Ovarian resistance using the follicle-to-oocyte index (FOI). Reprint
from Alviggi et al. (17).
of FSHR polymorphism on OS. The authors showed that higher
FSH consumption is expected in homozygotes for the A allele
of the FSHR (rs1394205) polymorphism than in carriers of the
G allele. Moreover, FSHR (rs6166) Serine carriers seem to be
less responsive to OS treatment, with fewer oocytes retrieved at
the end of OS than Asparagine carriers (22). In other words,
both Serine carriers of FSHR (rs 6166) and A carriers of
FSHR (rs1394205) are at increased risk of exhibiting ovarian
resistance to OS, which in turn might lead to a suboptimal
response concerning the number of retrieved oocytes at the end
of OS.
Ovarian hypo-responsiveness to gonadotropin stimulation
remains an undervalued issue in ART both in research and
in daily clinical practice. Not surprisingly, the prevalence
of this condition is still unclear. However, preliminary data
show that ∼10% of women defined as normal responders by
demographic characteristics and ovarian reserve testing requires
a higher than expected total dosage of gonadotropin to promote
adequate follicular development (36). Notably, a recent study
indicated that approximately 45% of patients aged 18–40 years
who underwent conventional OS using FSH doses of 150–
225 IU/day retrieved <10 oocytes at their first stimulation
cycle (12, 37). These data may be overestimated as the authors
did not specify the ovarian reserve before stimulation. By
examining the data from a group of 427 consecutive infertile
women who underwent conventional OS in one of the authors’
(SCE) clinic, 47% of the treated patients fitted the POSEIDON
criteria. Among them, 5 and 35% were within groups 1 and
2 categories, respectively (38). Although larger studies are
required, these preliminary data suggest that a remarkable
number of women with adequate pre-stimulation ovarian reserve
parameters exhibits an unexpected anomalous response to
gonadotropin stimulation.
CLINICAL MANAGEMENT OF POSEIDON’S
GROUPS 1 AND 2 PATIENTS
As highlighted above, there is a significant number of women
classified as normal responders—based on ovarian markers—
who show resistance to exogenous gonadotropin stimulation.
Unlike those with diminished ovarian reserve in which the
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FIGURE 3 | Pathogenesis of low follicle-to-oocyte index (FOI). Reprint from Alviggi et al. (17).
increment of gonadotropin dosage during ovarian stimulation
appears to be of limited value (39), POSEIDON’s groups
1 and 2 patients seem to benefit from a pharmacological
intervention concerning the OS protocol. Given the possibility
of the existence of a polygenic trait in POSEIDON’s groups
1 and 2 patients, an option would be for clinicians to assess
normal ovarian reserve patients concerning the most common
polymorphisms in case of an unexpected poor (≤3 oocytes)
or suboptimal response (4–9 oocytes) in previous IVF cycle.
Ideally, if large randomized controlled trial confirmed the
utility of pharmacogenomic approach, genotype screening could
be potentially recommended even before ovarian stimulation
avoiding inadequate OS attempts.
Patients with specific polygenetic traits would be at high
risk of being classified as POSEIDON’s groups 1 and 2
after conventional OS using empirical approaches. Thus, such
patients could be identified a priori and treated accordingly
using a pharmacogenomic rather than a trial and error
approach. Indeed, pharmacogenomic algorithms have been
used to evaluate how genetic differences among individuals
might affect drug response, thus ultimately leading to the
development of personalized drug therapies to compensate for
these differences (30). The individual genomic variation could
influence sensitivity to antimicrobials and response to cancer
strategies (40).
Furthermore, genetic traits could influence fertility, including
ovarian response to gonadotropin stimulation (41, 42), despite
no obvious clinical signs or symptoms. These polymorphisms
are widespread in population and women with infertile disorders
(43). Considering that genotype analysis could be provided
at lower cost compared with the past, it is plausible that a
genotype mapping of women who showed an unexpected low
response during OS could be of use to optimized management
strategy in such women. Nevertheless, since the availability
of polymorphism panel testing is still limited, another option
would be to apply empirical pharmacological interventions to
increase the oocyte yield—and eventually pregnancy outcomes—
in such patients.
Estimating the Number of Oocytes Needed
to Obtain at Least One Euploid Blastocyst
for Transfer
In 2016, the POSEIDON group introduced a new marker of
success in ART, namely, the ability to retrieve the number
of oocytes needed to obtain at least one euploid embryo for
transfer (38). This marker represents a logical endpoint to
guide clinicians develop an individualized treatment plan for
ART patients, including those of POSEIDON’s groups 1 and
2. Indeed, availability of a euploid embryo for transfer may
change the fate of the low prognosis patient, as ∼50–60%
euploid blastocysts implant across all age categories (44). Thus,
the higher the number of oocytes retrieved, the higher the
probability of obtaining an embryo cohort that may include at
least one euploid blastocyst (45, 46). However, retrieval of an
optimal number of oocytes may not be feasible in patients of
groups 1 and 2 due to reasons discussed in previous sections.
The matter is further worsened by female age, which is the most
critical predictor of embryo euploidy. In a recent study, using
preimplantation genetic testing data of patients undergoing
ART, we showed that blastocyst euploidy not only markedly
decreases with female aging but also that the magnitude of
decrease is progressive with every year of age (46). It would be
therefore useful to estimate the individualized minimum number
of oocytes needed to achieve at least one euploid blastocyst for
transfer. A pretreatment predictive model—the ART Calculator-
has been developed to assist clinicians to counsel and plan
treatment regarding the number of oocytes required for at least
one euploid blastocyst in IVF/ICSI procedures. Briefly, the
model was constructed based on the results of the LASSO (Least
Absolute Shrinkage and Selection Operator) regression analysis,
which was utilized for both variable selection and regularization
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to enhance the prediction accuracy and interpretability of the
statistical model. It is out of the scope of this paper to discuss
the technical aspects of the calculator, but detailed information
is provided in other papers within this Frontiers Research
Topic. The “ART Calculator” is available online at http://www.
groupposeidon.com/ and is fully aligned with the POSEIDON
marker of successful outcome.
Individualized Controlled Ovarian
Stimulation
Based on limited data, five main strategies might be
considered, which can be used alone or combined, namely
(i) use of recombinant FSH in preference over urinary
gonadotropin preparations, (ii) FSH dose increase, (iii) rec-LH
supplementation, (iv) Dehydroepiandrosterone supplementation
before OS, and (v) the combination of follicular and luteal phase
stimulation in the same ovarian cycle. A flow chart listing the
suggested management of Posedoin group 1 and 2 is illustrated
in Figure 4.
Use of Recombinant FSH
The main problem behind suboptimal response or poor response
is that the number of retrieved oocytes might not be consistent
with the ovarian reserve. With the aim to retrieve more oocytes
FIGURE 4 | Suggested management of Poseidon groups 1 and 2 patients.
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at the beginning of stimulation, a more “potent” gonadotropin
formulation should be considered. Several randomized
controlled trials and meta-analyses demonstrated that the use of
recombinant formulations is associated with significantly higher
number of retrieved oocytes than with urinary formulations
irrespectively of the pituitary suppression strategy (47–49). These
findings seem to relate to the higher bio-potency of recombinant
formulations (50). In conclusion, the use of more potent (rFSH)
recombinant formulation might be suggested in Poseidon Group
1 and 2.
FSH Dose Increase
Serine carriers of FSHR polymorphism undergoing OS for ART
seem to benefit from increased recombinant FSH doses. In
this regard, the first attempt to develop a pharmacogenomic
approach to OS was conducted by Behre et al. (51). In their
study, Ser680/Ser680 carriers were randomly allocated to two
subgroups to receive a daily rec-FSH dose of 150 IU or 225 IU.
The dose of 225 IU/day was able to restore the estradiol levels
at the end of OS in Ser680/Ser680 carriers, which was similar
to that of women with the wild-type genotype (51). Along the
same lines, Genro et al. showed that when a high FSH dose (300
IU per day) was given, the FORT index was not significantly
different in patients undergoing OS for ART, regardless of FSHR
rs6166 genotype distribution (52). As for the FSHR rs1394205
polymorphism, we are unaware of any trials examining the effect
of increased FSH doses. Furthermore, increasing FSH dosage
appears to be a valid strategy in women with a history of
suboptimal response per se. Specifically, a 2018 retrospective
analysis evaluated the effect of FSH dose adjustment in women
with a history of suboptimal response (4–9 oocytes retrieved)
after conventional OS (37). In this study, 160 women <40 years
with normal ovarian reserve undergoing their second ovarian
stimulation cycle in a fixed gonadotropin-releasing hormone
(GnRH) antagonist protocol with daily recombinant FSH (rFSH)
were recruited. A dose increment of rFSH in the subsequent cycle
carried out 4 months later on average lead to higher number of
oocytes retrieved (9 vs. 6, p < 0.001) and good quality embryos
(4 vs. 3, p < 0.001) than that of previous cycle. A regression
analysis showed that an increase of 50 IU of the initial rFSH
dose would lead to 1 more oocyte. Although there is evidence
that resistance in term of the number of oocytes retrieved and
follicle output rate could be associated with specific genotype
anomalies, the suboptimal responders were not tested for genetic
polymorphisms in this study.
Recombinant Luteinizing Hormone Supplementation
Several trials have examined the clinical utility of adding
recombinant LuteinizingHormone (rLH) in womenwith ovarian
resistance to gonadotropin (53–58). In the larger ones, the
ovarian resistance was identified in the form of an “initial slow
response” in follicle growth (54, 55). In others, involving a
lower number of cases, the hypo-response was retrospectively
diagnosed in women who required higher-than-expected doses
of gonadotropins considering their age, body mass index, and
ovarian reserve (53, 56). Data from the more robust studies
indicate that in slow responders, LH supplementation starting
from stimulation days 7–10 might be more efficient than
increasing the dosage of rFSH to rescue the ongoing cycle.
In detail, Ferraretti et al. study was a single-center randomized
trial involving a total of 126 women aged 37 or younger
undergoing pituitary suppression with the agonist protocol. The
number of oocytes retrieved was significantly higher in hypo-
responders treated with the rFSH plus rLH step-up regimen
than in those who received a higher dose of rFSH (11.1 vs.
8.2, p < 0.05). Along the same lines, higher pregnancy rates
per embryo transfer (54 vs. 24.4%, p < 0.05), live birth rates
(40.7 vs. 22%, p < 0.005) and implantation rate (36.8 vs. 14.1%,
p < 0.05) were observed in women supplemented with rLH
than in those who received only an increment of rFSH. Another
study was a multicenter RCT involving 229 IVF/ICSI cycles (55).
The population, definition of hypo-response, and OS regimen
were similar to Ferraretti et al. study. In this trial, the number
of oocytes retrieved was significantly higher in patients who
received rLH supplementation (9.0 ± 4.3) than in those treated
with increased rFSH dosage (6.1± 2.6, P< 0.01). The use of rLH
supplementation was able to restore both rescue implantation
(14.2 vs.18.1%, p > 0.05) and ongoing pregnancy rates (32.5 vs.
40.2%, p > 0.05), which turned out to be resulted similar to that
observed in normal responders. Regarding dosage, the use of 150
IU of rLH is apparently better than the use of 75 IU in the long
GnRH agonist protocol (59). In a randomized trial, 46 hypo-
responders identified by similar criteria as in Ferraretti et al. and
De Placido et al. studies (54, 55) were randomized to receive a
supplementation with 150IU or 75IU of rLH, respectively. Hypo-
responders supplemented with 150 IU/day of rLH had higher
number of oocytes retrieved (9.65 ± 2.16 vs. 6.39 ± 1.53, p <
0.05) and showed higher percentage of mature oocytes (79 vs.
65.7%, p < 0.05) than in those supplemented with 75 IU/day of
rLH (59).
More recently, Yilmaz et al. (60) performed a single-
center prospective study that corroborated the results of the
randomized controlled trials mentioned above. In their study,
hypo-responders were identified as in De Placido et al. study.
A total of 137 patients were enrolled, 85 of whom had a hypo-
response to OS diagnosed on stimulation on day 7 (at least
six follicles between 6 and 10mm; no follicle over 10mm, and
Estradiol levels below 180 pg/mL), and 52 had a normal response
(regular follicular growth and Estradiol level >180 pg/mL). In
the hypo-response group, 50 women received 75 IU daily of
rLH, whereas the rFSH dosage was increased by 75 UI in the
remaining 35. Implantation rates were significantly higher in
controls (34.7%) and in the rLH supplementation (36.1%) groups
than in the increased-dose rFSH group (15%, P < 0.02). The
pregnancy rates were also higher in the two former groups than
in the latter group (64.7 and 57.8%, respectively vs. 32.4%, P <
0.05). The findings of the studies mentioned above should be
interpreted with caution because the GnRH agonist long protocol
was utilized in all studies. Currently, there are no data concerning
the use of rLH supplementation to hypo-responders undergoing
OS under a GnRH antagonist regimen.
The mechanism by which rLH exerts its beneficial effect
in hypo-responders is not fully understood. Although it was
advocated that the excessive suppression of endogenous LH after
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down-regulation with GnRH analogs may create the need for
exogenous LH supplementation, neither Ferraretti et al. nor De
Placido et al. found a significant association between serum
LH levels during OS and the response to rLH supplementation
(54, 55, 61). A more plausible hypothesis would be related to
genetically determined characteristics of LH itself or its receptors.
Indeed, Alviggi et al. (36, 41) demonstrated that carriers of LH β
chain variant had ovarian resistance to exogenous gonadotropin
and required a higher dosage of recombinant FSH during OS
(36). This variant was initially discovered by Pettersson and
Söderholm (62) as an immunologically anomalous form of LH
caused by two-point mutations in the β subunit gene, both
altering the amino acid sequence (Trp8Arg and Ile15Thr). The
LH variant has elevated bioactivity in vitro but significantly
shorter (5–9min) half-life in circulation than the wild-type
LH (12–22min) (63). This variant is common worldwide, with
carrier frequency varying from 0 to 52% in various ethnic
groups. Its incidence in Italy ranges between 12 and 13%.
Another polymorphism that might be implicated in impaired
ovarian response relates to those altering the Luteinizing
hormone/human chorionic gonadotropin receptors (LHCGR)
(64, 65). Specifically, a prospective cohort study investigated
the effect of multiple gonadotropin polymorphisms on ovarian
response in 94 normogonadotropic Caucasian women who
underwent OS with a starting dose of 150 IU of recombinant FSH
daily. In this study, the presence of allele C on both FSHR-min29
and LHCGR-291 was associated with an increased ratio between
the cumulative r-FSH consumption and the total number of
oocytes as well as mature oocytes (RR: 5.47, CI 95%: 3.13–7.81,
p< 0.001) (65).
Lastly, a 2018 systematic review and a further meta-
analysis evaluating the role of rLH in ART concluded that
adding rLH to the stimulation protocol could be beneficial in
two subgroups of patients, namely, (i) women with adequate
prestimulation ovarian reserve parameters and an unexpected
hyporesponse to rFSH monotherapy, and (ii) those with 36–
39 years of age (57, 66). As discussed in the previous sections,
many patients classified as POSEIDON’s groups 1 and 2
will fit in the former subgroup. It seems, therefore, sound
to consider adding rLH to OS. For them, 75–150 IU rLH
can be started at the mid-follicular phase in an attempt
to rescue the ongoing cycle or at stimulation day 1 in a
subsequent cycle.
Dehydroepiandrosterone
Dehydroepiandrosterone (DHEA) supplementation before OS
has been proposed to counteract the age-related fertility decline
(67–69). A last Cochrane meta-analysis including 12 RCTs
concluded that pretreatment with DHEA could significantly
improve live birth rate in poor responders and in advanced age
women (69). Two RCTs trials was conducted in women fitting
Poseidon groups 2, namely those characterized by advanced
age and good ovarian reserve (70, 71). In detail, Tartagni et al.
conducted a RCT including 109 women between 35-40 years
old with good ovarian reserve (i.e., AMH levels above 2 ng/mL).
Patients recruited were assigned to DHEA supplementation (n
= 53, 75 mg/die) or placebo (n = 56) eight weeks before OS.
Higher live birth rate (22/53 vs. 18/56, p < 0.05) and lower
miscarriage rate (0/53 vs. 5/56, p< 0.05) was observed in women
supplemented with DHEA than in the placebo group. Similar
findings was observed by Moawad et al. (71) in another RCT
in which population study was randomized to receive DHEA
(75mg/die) supplementation for 12 weeks before OS. Indeed,
higher ongoing pregnancy rate (11/58 vs. 7/47, p < 0.05),
was observed in women supplemented with DHEA versus no
supplemented group. The rational behind the use of androgens
could be related to the fact that an impaired theca function and
androgens production is observed in advanced age women (72).
Notably, it was observed that rFSH administration alone is not
able to sustain androgens production in advanced age women
(73). Furthermore, these findings corroborate the hypothesis that
LH supplementation, which is the main regulator of theca cells,
could be of use in advanced age women.
Double Stimulation in the Same Ovarian Cycle
A novel controlled ovarian stimulation approach has been
proposed in women of low prognosis as a mean to increase the
number of retrieved oocytes and the number of blastocyst
available to biopsy for preimplantation genetic test for
aneuploidies (PGT-A) in a single ovarian cycle (74). This
method, referred to as “DuoStim,” combines the conventional
follicular phase stimulation (FPS) with luteal phase stimulation
(LPS). In both the FPS and LPS, patients undergo co-treatment
with a maximal dose of rFSH (300 IU/day) plus rLH (150
IU/day) using a GnRH antagonist regimen (75) (Figure 4). The
final maturation of oocytes in FPS and LPS was triggered by a
subcutaneous bolus of buserelin (dose 0.5mL) to reduce the time
of luteolysis and the second stimulation started five days after
the first retrieval. The DuoStim protocol might be considered
a putative strategy in patients classified as Poseidon’s groups
2 and 4, who are characterized by advanced maternal age. In
this regards, a case-control study included 188 poor prognosis
patients undergoing DuoStim with PGT-A, fitting at least two
of the following conditions: poor ovarian reserve (i.e., AMH
< 1.5 ng/mg, AFC ≤ 6), advanced maternal age (≥35 years)
and history of few numbers of metaphase II (MII) oocytes (≤5)
demonstrated that oocytes/embryos derived from LPS showed
similar oocytes competence as FPS-derived ones. Moreover, the
authors provided evidence that on average more MII oocytes can
be retrieved after LPS than after FPS (75, 76). Therefore, in these
patients maximizing the number of oocytes would result in a
dramatically higher opportunity to obtain a competent embryo
per menstrual cycle in comparison to conventional stimulation.
DuoStim was then explored in a large multicentre experience
involving 310 women indicated to PGT-A, which confirmed
comparable fertilization, blastocyst, euploidy, and pregnancy
rates after euploid single-embryo-transfer oocytes/embryos from
the FPS and LPS. In turn, the rate of patients obtaining at least
one euploid blastocyst significantly increased from 42.3% (n
= 131/310) after FPS-only to 65.5% (n = 203/310) with the
contribution of LPS (77). Nevertheless, these results should
be interpreted with caution since the treated patients did not
explicitly fulfill the Poseidon groups 1–2 criteria. Thus, since
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promising, the use of DuoStim in Poseidon Groups 2 patients
should be investigated further.
CONCLUSIONS
Infertile patients undergoing ART may respond poorly (<4
oocytes retrieved) or suboptimally (4–9 oocytes retrieved) to
gonadotropin stimulation despite the presence of adequate
ovarian parameters. According to the new POSEIDON’s criteria
of low prognosis patients undergoing ART, they are classified
as group 1 if younger than 35 years-old or group 2 if ≥35
years-old. Both groups are likely to have lower cumulative live
birth rates than normal or high responders, an effect that is
modulated by age. The pathophysiology mechanisms explaining
this phenomenon are not fully understood but seem to be
mainly associated with a polygenic trait involving gonadotropins
and their receptors. The primary goal of management in
POSEIDON’s groups 1 and 2 patients is to maximize oocyte yield
as to increase the likelihood of having at least one euploid embryo
for transfer. For this, indices such as FORT (follicle output rate)
and FOI (follicle-to-oocyte index) should be used to both identify
the subset of hypo-responders and to determine if the ovarian
reserve was adequately explored during a previous stimulation.
Moreover, testing for the presence of common
polymorphisms affecting gonadotropins and/or their receptors
might be considered in women belonging to Poseidon groups
1 and 2. Added to this, an individualized estimation of the
number of oocytes needed to achieve at least one blastocyst
for transfer-for instance, using the ART calculator- can
make treatment more focused and cost-effective. Given the
overlapping between POSEIDON’s groups 1 and 2 categories and
hypo-response to OS, several pharmacological interventions may
be considered as regards clinical management of such patients.
According to the best available literature, there are at least five
strategies to be considered, which are not mutually exclusive,
namely (i) use of recombinant FSH in preference over urinary
gonadotropin preparations, (ii) FSH dosage increase, (iii) use of
rLH supplementation, (iv) Androgens supplementation before
OS, (v) DuoStim. Nevertheless, no trial explicitly examining the
role of interventions to POSEIDON’s groups 1 and 2 patients has
been carried out yet. The introduction of POSEIDON criteria
and practical indices such as FOI, along with polymorphism
testing, could help to understand better this specific subgroup of
patients undergoing ART. Also, such an approach can be used to
design robust clinical trials aiming at finding the optimal clinical
management, thus making it an area open for further research.
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